Landscape of toxin-neutralizing therapeutics for snakebite envenoming (2015-2022): Setting the stage for an R&D agenda.

Autor: Borri J; Policy Cures Research, Sydney, New South Wales, Australia., Gutiérrez JM; Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José, Costa Rica., Knudsen C; VenomAid Diagnostics, Lyngby, Denmark., Habib AG; Infectious and Tropical Diseases Unit, Department of Medicine, Bayero University, Kano, Nigeria., Goldstein M; Policy Cures Research, Sydney, New South Wales, Australia., Tuttle A; Policy Cures Research, Sydney, New South Wales, Australia.
Jazyk: angličtina
Zdroj: PLoS neglected tropical diseases [PLoS Negl Trop Dis] 2024 Mar 26; Vol. 18 (3), pp. e0012052. Date of Electronic Publication: 2024 Mar 26 (Print Publication: 2024).
DOI: 10.1371/journal.pntd.0012052
Abstrakt: Background: Progress in snakebite envenoming (SBE) therapeutics has suffered from a critical lack of data on the research and development (R&D) landscape. A database characterising this information would be a powerful tool for coordinating and accelerating SBE R&D. To address this need, we aimed to identify and categorise all active investigational candidates in development for SBE and all available or marketed products.
Methodology/principal Findings: In this landscape study, publicly available data and literature were reviewed to canvas the state of the SBE therapeutics market and research pipeline by identifying, characterising, and validating all investigational drug and biologic candidates with direct action on snake venom toxins, and all products available or marketed from 2015 to 2022. We identified 127 marketed products and 196 candidates in the pipeline, describing a very homogenous market of similar but geographically bespoke products and a diverse but immature pipeline, as most investigational candidates are at an early stage of development, with only eight candidates in clinical development.
Conclusions/significance: Further investment and research is needed to address the shortfalls in products already on the market and to accelerate R&D for new therapeutics. This should be accompanied by efforts to converge on shared priorities and reshape the current SBE R&D ecosystem to ensure translation of innovation and access.
Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: JMG works at Instituto Clodomiro Picado (Universidad de Costa Rica), a public research centre and antivenom manufacturer. CK works at VenomAid Diagnostics, a private company researching diagnostics for snakebite.
(Copyright: © 2024 Borri et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje